While its expression is most concentrated in these areas, it is also present in the lungs, heart, kidneys, digestive system, liver, skeletal muscles, and peripheral nervous system to a lesser extent [27, 28] (Fig
Employers discontinuing coverage of GLP-1 medications should be aware that the health benefits their members attain will likely be lost over a little more than a year unless the members find a way to continue on these medications.
Overall, no causal link has ever been established between MT-II and cancer and importantly, the homologous synthetic peptide, MT-1, is FDA-approved and operates via the same mechanism of action with respect to activation of melanocortin receptors in melanocytes [7]
Rubicon depletion in adipocytes was also shown to reduce body weight and sWAT, vWAT, and BAT mass [83], indicating that inhibiting autophagy may postpone metabolic diseases during aging
Research published in 2025 confirmed that 26 to 40% of weight lost on GLP-1 medications is lean tissue, not fat
